Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Andrew Davies: EHA 2020 lymphoma highlights

Andrew Davies • 19 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma AUTO3 CAR-T Inotuzumab ozogamicin Loncastuximab tesirine Rituximab
ALEXANDER IELSG 37 INCA

Andrew Davies, BSc, BM, MRCP, PhD, of the University of Southampton, Southampton, UK, explores exciting updates in lymphoma presented at EHA 2020. Dr Davies discusses the NCRI INCA study evaluating inotuzumab ozogamicin plus rituximab for diffuse large B-cell lymphoma (DLBCL) patients ineligible for R-CHOP chemotherapy, CAR T-cell therapies such as AUTO3 evaluated in the ALEXANDER study (NCT03287817) and recent trials investigating loncastuximab tesirine, an antibody-drug conjugate, in relapsed/refractory DLBCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
Economic burden of CAR-T therapy from a UK perspective
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals